NYSE:MD

Stock Analysis Report

Executive Summary

MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico.

Snowflake

Fundamentals

Undervalued with imperfect balance sheet.

Risks

  • MEDNAX has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has MEDNAX's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.8%

NYSE:MD

-1.3%

US Healthcare

-1.0%

US Market


1 Year Return

-53.6%

NYSE:MD

-5.3%

US Healthcare

-0.4%

US Market

MD underperformed the Healthcare industry which returned -5.3% over the past year.

MD underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

MDIndustryMarket
7 Day0.8%-1.3%-1.0%
30 Day-8.3%-2.3%-3.3%
90 Day-17.1%4.4%0.8%
1 Year-53.6%-53.6%-3.9%-5.3%1.9%-0.4%
3 Year-66.5%-66.5%28.2%22.9%39.4%30.4%
5 Year-61.8%-61.8%70.8%60.7%54.2%37.1%

Price Volatility Vs. Market

How volatile is MEDNAX's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MEDNAX undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

MEDNAX's share price is below the future cash flow value, and at a moderate discount (> 20%).

MEDNAX's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

MEDNAX is good value based on earnings compared to the US Healthcare industry average.

MEDNAX is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

MEDNAX is poor value based on expected growth next year.


Price Based on Value of Assets

MEDNAX is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is MEDNAX expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

6.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

MEDNAX's revenue is expected to grow by 2.4% yearly, however this is not considered high growth (20% yearly).

MEDNAX's earnings are expected to grow by 6% yearly, however this is not considered high growth (20% yearly).

MEDNAX's revenue growth is positive but not above the United States of America market average.

MEDNAX's earnings growth is positive but not above the United States of America market average.

MEDNAX's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

MEDNAX is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has MEDNAX performed over the past 5 years?

-3.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

MEDNAX's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

MEDNAX's 1-year earnings growth is negative, it can't be compared to the 5-year average.

MEDNAX's 1-year earnings growth is negative, it can't be compared to the US Healthcare industry average.


Return on Equity

MEDNAX has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

MEDNAX used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

MEDNAX's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is MEDNAX's financial position?


Financial Position Analysis

MEDNAX is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

MEDNAX's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

MEDNAX's level of debt (76.3%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (7.5% vs 76.3% today).

Debt is not well covered by operating cash flow (15.9%, less than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 4x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.5x debt.


Next Steps

Dividend

What is MEDNAX's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate MEDNAX's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate MEDNAX's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as MEDNAX has not reported any payouts.

Unable to verify if MEDNAX's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as MEDNAX has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of MEDNAX's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of MEDNAX's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Roger Medel (72yo)

16.4yrs

Tenure

US$9,938,017

Compensation

Dr. Roger J. Medel, M.D., Co-Founded at MEDNAX, Inc. (also known as Pediatrix Medical Group Inc.) in 1979. Dr. Medel served as the MEDNAX, Inc.’s President until May 2000 and as Chief Executive Officer unt ...


CEO Compensation Analysis

Roger's remuneration is higher than average for companies of similar size in United States of America.

Roger's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

2.6yrs

Average Tenure

52yo

Average Age

The tenure for the MEDNAX management team is about average.


Board Age and Tenure

15.3yrs

Average Tenure

66yo

Average Age

The average tenure for the MEDNAX board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

More shares have been bought than sold by MEDNAX individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$2,613,65213 Aug 19
Michael Fernandez
EntityIndividual
Role
Member of the Board of Directors
Shares122,409
Max PriceUS$21.35
BuyUS$8,146,92712 Aug 19
Michael Fernandez
EntityIndividual
Role
Member of the Board of Directors
Shares377,591
Max PriceUS$21.68
SellUS$100,33115 Mar 19
Pascal Goldschmidt
EntityIndividual
Role
Member of the Board of Directors
Shares3,300
Max PriceUS$30.40
SellUS$40,630,80920 Sep 18
Elliott Management Corporation
EntityCompany
Shares859,000
Max PriceUS$48.57

Ownership Breakdown


Management Team

  • Claire Fair

    Chief Human Resources Officer

    • Tenure: 0.6yrs
  • Charles Lynch

    Vice President of Strategy & Investor Relations

  • James Swift

    Chief Development Officer

    • Tenure: 5.7yrs
  • Steve Farber (49yo)

    Executive VP & CFO

    • Tenure: 0.8yrs
    • Compensation: $5.75m
  • David Clark (52yo)

    Chief Operating Officer

    • Tenure: 0.5yrs
    • Compensation: $3.95m
  • Dominic Andreano (50yo)

    Senior VP

    • Tenure: 7.3yrs
    • Compensation: $2.01m
  • Mary Ann Moore

    Chief Compliance Officer

    • Tenure: 0.6yrs
  • Tony Ambegaoker

    Corporate Chief Information Officer

    • Tenure: 2.6yrs
  • John Pepia (56yo)

    Senior VP & Chief Accounting Officer

    • Tenure: 3.3yrs
  • Roger Medel (72yo)

    Co-Founder

    • Tenure: 16.4yrs
    • Compensation: $9.94m

Board Members

  • Cesar Alvarez (71yo)

    Chairman of the Board

    • Tenure: 15.3yrs
    • Compensation: $250.01k
  • Waldemar Carlo (66yo)

    Director

    • Tenure: 20.2yrs
    • Compensation: $210.01k
  • Karey Barker (51yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: $200.01k
  • Paul Gabos (53yo)

    Director

    • Tenure: 16.8yrs
    • Compensation: $220.01k
  • Carlos Migoya (68yo)

    Director

    • Tenure: 0.3yrs
  • Manuel Kadre (53yo)

    Lead Independent Director

    • Tenure: 5.4yrs
    • Compensation: $235.01k
  • Enrique Sosa (79yo)

    Director

    • Tenure: 15.3yrs
    • Compensation: $200.01k
  • Pascal Goldschmidt (64yo)

    Director

    • Tenure: 13.4yrs
    • Compensation: $210.01k
  • Roger Medel (72yo)

    Co-Founder

    • Tenure: 40.6yrs
    • Compensation: $9.94m
  • Mike Fernandez (66yo)

    Director

    • Tenure: 23.8yrs
    • Compensation: $200.01k

Company Information

MEDNAX, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MEDNAX, Inc.
  • Ticker: MD
  • Exchange: NYSE
  • Founded: 1979
  • Industry: health care services
  • Sector: healthcare
  • Market Cap: US$1.796b
  • Shares outstanding: 82.90m
  • Website: Click here

Number of Employees


Location

  • MEDNAX, Inc.
  • 1301 Concord Terrace
  • Sunrise
  • Florida
  • 33323
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDNYSE (New York Stock Exchange)YesCommon StockUSUSDSep 1995
PDCDB (Deutsche Boerse AG)YesCommon StockDEEURSep 1995
MD *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNSep 1995

Biography

MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the Uni ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 00:36
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.